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TBackground: Autologous adult stem cell transplantation has been touted as the latest
tool in regenerative medical therapy. Its potential for use in cardiovascular disease
has only recently been recognized. A randomized study was conducted with a novel
epicardial technique to deploy stem cells as an adjuvant to conventional revascu-
larization therapy in patients with congestive heart failure.
Methods: After institutional review board and government approval, adult autolo-
gous stem cell transplantation (CD34) was performed in patients with ischemic
cardiomyopathy and an ejection fraction of less than 35% who were scheduled for
primary off-pump coronary artery bypass grafting. Preoperatively, the patients
underwent echocardiography, stress thallium imaging single photon emission com-
puted tomography, and cardiac catheterization to identify ischemic regions of the
heart and to guide in the selection of stem cell injection sites. The patients were
prospectively randomized before the operative therapy was performed. Patient
follow-up was 1, 3, and 6 months with echocardiography, single photon emission
computed tomography, and angiography.
Results: There were 20 patients enrolled in the study. Ten patients had successful
subepicardial transplantation of autologous stem cells into ischemic myocardium.
The other 10 patients, the control group, only had off-pump coronary artery bypass
grafting. There were 8 male and 2 female subjects in each group. The median
number of grafts performed was 1 in both groups. On angiographic follow-up, all
grafts were patent at 6 months. The ejection fractions of the off-pump coronary
artery bypass grafting group versus the off-pump coronary artery bypass grafting
plus stem cell transplantation group were as follows: preoperative, 30.7%  2.5%
versus 29.4%  3.6%; 1 month, 36.4%  2.6% versus 42.1%  3.5%; 3 months,
36.5% 3.0% versus 45.5% 2.2%; and 6 months, 37.2% 3.4% versus 46.1% 1.9%
(P  .001). There were no perioperative arrhythmias or neurologic or ischemic
myocardial events in either group.
Conclusions: Autologous stem cell transplantation led to significant improvement in
cardiac function in patients undergoing off-pump coronary artery bypass grafting for
ischemic cardiomyopathy. Further investigation is required to quantify the optimal
timing and specific cellular effects of the therapy.
Congestive heart failure (CHF) is a complex clinical syndrome that resultsfrom myocardial dysfunction that impairs the heart’s ability to circulateblood at a rate sufficient to maintain the metabolic needs of peripheral
tissues and various organs. Heart failure is a relatively common clinical disorder
estimated to affect more than 5 million patients in the United States. About 400,000
new patients are diagnosed with CHF each year. Morbidity and mortality rates are
high; annually, approximately 900,000 patients require hospitalization for CHF, and
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ETup to 200,000 patients die from this condition. The average
annual mortality rate is 40% to 50% in patients with severe
(New York Heart Association [NYHA] class IV) heart
failure. In the United States CHF treatment is estimated to
cost more than 25 billion dollars for 2004.1
The initial stages of heart failure are managed with
medical therapy, and end-stage heart failure is managed
with surgical procedures in addition to medical therapy.
Some of the proven surgical procedures include myocardial
revascularization, ventricular assist devices, and heart trans-
plantation.2
Although surgical and catheter-based revascularization
of ischemic myocardium can treat angina, reduce the risk of
myocardial infarction, and improve function of viable myo-
cardium, the viability of severely ischemic myocardium,
necrotic myocardium, or both cannot be restored.
The major process to reverse the left ventricular remod-
eling would be the enhancement of regeneration of cardiac
myocytes, as well as the stimulation of neovascularization
within the affected area of the myocardium.3 Thus the aim
of cardiac cellular transplantation is to repopulate the ailing
myocardium with cells that could restore contractility and
blood supply. This can be achieved by introducing progen-
itor cells that are capable of differentiating into cardiac
myocytes or that promote neovascularization. It has been
well established that adult bone marrow is a rich reservoir of
tissue-specific stem and progenitor cells. Several studies
have shown that bone marrow–derived cells functionally
contribute to neoangiogenesis during wound healing and
limb ischemia,4-14 postmyocardial infarction,15-19 endothe-
lialization of vascular grafts,20-23 atherosclerosis,24 retinal
and lymphoid organ neovascularization,25-27 and vascular-
ization during neonatal growth.28
In human subjects whole autologous bone marrow
mononuclear cells have been delivered by means of arterial
and venous catheters into the coronary vessels feeding the
infarcted and ischemic tissue,29-32 by means of transendo-
cardial injections,33 by means of guided electrochemical
mapping directly into infarcted myocardium,34 or by means
of direct epicardial injections.35 In another study the effi-
cacy of the ex vivo expanded peripheral blood mononuclear
cells was compared with bone marrow–derived endothelial
Abbreviations and Acronyms
CHF  congestive heart failure
GCSF  granulocyte colony-stimulating factor
NYHA  New York Heart Association
OPCAB off-pump coronary artery bypass grafting
PBS  phosphate-buffered saline
SPECT  single photon emission computed tomographyprogenitor cells in restoring revascularization after acute
1632 The Journal of Thoracic and Cardiovascular Surgery ● Decmyocardial infarction.36 In all of these studies, there was
improved blood flow and left ventricular function, suggest-
ing that infusion of autologous progenitor cells appears to
be feasible and safe and might confer short-term therapeutic
benefit.
The above data suggest that bone marrow or mobilized
peripheral blood progenitor cells play a role in the revascu-
larization of the ischemic myocardium. Most of these stud-
ies, however, are small series or case reports, are poorly
controlled, and are not randomized. There is lot of variabil-
ity in the factors and conditions to validate the true benefits
of cellular therapy. Therefore the goal of this study was to
perform a prospective randomized study of autologous stem
cell therapy in patients with ischemic CHF requiring
revascularization.
Methods
After hospital institutional review board and Argentina Ministry of
Health approval, patients with documented ischemic heart failure
were screened to evaluate suitability for the study protocol. All
patients underwent preoperative electrocardiography, 2-dimensional
stress echocardiography, single photon emission computed tomog-
raphy (SPECT), chest roentgenography, and standard hematologic
laboratory tests for general anesthesia and cardiac surgery. Inclu-
sion criteria were as follows: ischemic heart failure with an ejec-
tion fraction of 35% or less on 2 imaging studies (echocardiogra-
phy and multiplanar cardiac catheterization) and NYHA heart
failure functional class III or IV. All patients had prior percutane-
ous coronary interventions and had optimal medical management
of their heart failure. All patients screened for participation in this
study were from the Benetti Foundation in Argentina, where the
standard of care involves hybrid revascularization procedures and
where anterior vessels are bypass grafted and posterior vessels are
stented. This might not be the case in other countries. Patients were
excluded if they had a current or prior malignancy, any hemato-
logic disorder, renal failure requiring dialysis, left ventricular
aneurysm, prior cardiac surgery, valvular disease requiring sur-
gery, preoperative steroid therapy, or were within 6 days of an
acute coronary event.
On the day of the operation, the patients were randomized to
off-pump coronary artery bypass grafting (OPCAB) or OPCAB
plus stem cell therapy by using a nonparticipant in the study to
pick a red ball (OPCAB plus stem cell therapy group) or blue ball
(OPCAB-only group). After this was determined, the patients were
given a general anesthetic, and monitoring lines were placed.
Patients in the OPCAB-only group had a standard sternotomy and
OPCAB performed with both apical suction and pressure stabili-
zation of the heart (Guidant Corp). Patients in the stem cell therapy
group were placed prone, and bone marrow was harvested from the
iliac bone in a sterile fashion after achievement of general anes-
thesia. To minimize the anesthetic time, we designed a special
multiholed harvest needle with a 60-mL syringe. It was introduced
into the iliac bone between both posterior iliac spines at both sides.
Using this technique, we were able to harvest 500 to 600 mL of
bone marrow with a minimal number of puncture sites. At least
250 mL of bone marrow must be harvested to continue with the
protocol. The harvested bone marrow was placed in a blood bag
ember 2005
Patel et al Evolving Technology
ETwith 10,000 U of heparin sulfate and 400 m of lysine acetylsa-
licylate to avoid platelet clumping. The bone marrow was filtered
on a 500-m filter followed by a 200-m filter. The resulting
solution was mixed with hydroethylstarch 6%. The supernatant
was centrifuged at 400g for 15 minutes. The cellular pellet was
resuspended in phosphate-buffered saline (PBS). The cell solution
was mixed 3:1 with a solution of 155 mmol/L NH4Cl, 10 mmol/L
KHCO3 and 0.1 mmol/L EDTA and set for 5 minutes at room
temperature. The solution was then centrifuged at 400g for 10
minutes. The pellet was washed with PBS and resuspended. The
cell suspension was placed over Ficoll Paque (1.077 density) 4:1
and centrifuged at 400g for 30 minutes. The upper layer was
aspirated, leaving the mononuclear cell layer at the interphase. The
interphase cells were transferred to a new conical tube with PBS
and centrifuged at 300g for 10 minutes. The supernatant was
completely removed, and the cell pellet was resuspended in PBS.
Cells counts were performed, and magnetic labeling with Isolex
300i was performed as per standard protocol for peripheral blood
progenitor cell products to obtain an enriched product of at least
70% CD34 cells. The resulting cell solution was resuspended in
30 mL of the patient’s own plasma and 10,000 U of heparin
sulfate.
After OPCAB, the preselected sites of myocardial dyskinesis
and akinesis, but not the infarcted regions, were injected with the
stem cell preparation by using a 22-gauge needle apparatus. The
injections were in the peri-infarcted, viable but dykinetic, or aki-
netic areas. There were no injections into the scar itself. The needle
apparatus does not have an end hole like most needles but only has
side holes. This reduces the amount of leakage that would be
generated during a standard needle with a distal end hole. The
injection placement was based on prior echocardiography and
SPECT viewing to determine ventricular wall thickness, prevent-
ing direct introduction of cells into the ventricle. The cell prepa-
ration was injected in 1.0-mL aliquots as the needle was withdrawn
from the myocardium over a 2-second period. The injections were
spaced up to 1 cm apart and spaced to avoid coronary vessels. The
injections were 3 to 5 mm in depth on the basis of echocardio-
graphic findings of wall thickness. No direct intracoronary injec-
tions were performed. Once this was completed, the chest was
closed in standard fashion after good hemostasis and placement of
drainage tubes. The patients were extubated in the operating room
and taken to the intensive care unit for monitoring. The patients
were transferred to the telemetry floor with continuous monitoring
and, when appropriate, discharged home. The patients were mon-
TABLE 1. Studies used to evaluate patients
Preoperative Postoperative, 1 wk 1 mo 3 mo 6 mo
ECG X X X X X
CXR X X X X X
SPECT X X X X
CATH X X
ECHO X X X X
ECG, Electrocardiogram; CXR, chest roentgenogram; SPECT, single photon
emission computed tomography; CATH, cardiac catheterization; ECHO,
echocardiography.itored-evaluated postoperatively as seen in Table 1.
The Journal of ThoracicBoth groups were followed in the same manner. Statistics were
performed by using a 2-way repeated measures analysis of vari-
ance, and this resulted in the ability to compare the increase in left
ventricular ejection fraction over time in the stem cell group with
the increase in left ventricular ejection fraction over time in the
control subjects (Statistica software, STAT Soft; see Tables E1-E4
and Figure E1). The Student paired t test for means was used to
compare the NYHA functional class preoperatively and 6 months
postoperatively for each group (Statistica software, STAT Soft; see
Tables E1-E4 and Figure 1). The study was blinded for the patients
and reviewers of the imaging studies (cardiologists).
Results
There were 48 patients screened for the study. Twenty
patients were enrolled and randomized into the study. The
demographics of the OPCAB versus OPCAB plus stem cell
therapy groups were as follows: male/female sex, 8:2 versus
8:2; mean age, 63.6 versus 64.8 years; and prior myocardial
infarction, 7 versus 9 patients. All 20 patients enrolled in the
study had successful completion of the treatment in their
respective study arms. Ten patients underwent successful
OPCAB, with grafting of the left internal thoracic artery to
the left anterior descending artery in the control group. In
the OPCAB plus stem cell therapy group, 10 patients un-
derwent successful OPCAB from the left internal thoracic
artery to the left anterior descending artery, and 1 patient
also underwent a saphenous vein graft to the circumflex
Figure 1. Effects of stem cell transplantation on LVEF recovery.
LVEF, Left ventricular ejection fraction; OPCAB, off-pump coro-
nary artery bypass grafting.artery. The median amount of bone marrow harvested was
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in the final specimen. The ejection fractions for preopera-
tive, 1-month, 3-month, and 6-month analyses are found in
Table 2 for the OPCAB-only group and Table 3 for the
OPCAB plus stem cell therapy group; Table 4 compares the
means of both groups. Also found in Tables 2 and 3 are the
ages and preoperative and postoperative (6-month) NYHA
functional classes of all the patients. The OPCAB-only
patients did have a decrease from 3.4 to 2.7 (P  .001).
However, there was even a larger decrease in the OPCAB
plus stem cell therapy group from 3.5 to 0.7 (P  5.9 
109). There was no statistical difference in the preopera-
tive ejection fractions between the 2 groups: 30.7%  2.5%
in the OPCAB group versus 29.4%  3.6% in the OPCAB
plus stem cell therapy group (P  .381). There was, how-
ever, a significant difference in ejection fractions at 1, 3, and
TABLE 2. Ejection fractions for the OPCAB-only group
OPCAB
patient no. Age (y)
NYHA class
preoperatively
NYHA class
post
operatively
Preoper
EF (%
1 71 IV III 30
2 64 III II 34
3 57 III III 32
4 66 III III 31
5 62 III II 29
6 60 IV II 33
7 55 III II 34
8 69 IV IV 29
9 68 IV III 26
10 64 III III 29
Mean  SD 63.6 4.9 3.4 2.7 30.7
OPCAB, Off-pump coronary artery bypass grafting; NYHA, New York He
end-diastolic volume; SD, standard deviation.
TABLE 3. Ejection fractions for the OPCAB plus stem cell
SC patient
no. Age (y)
NYHA class
preoperatively
NYHA class
postoperatively
Preope
EF
1 56 IV I 2
2 76 III 0 3
3 72 IV II 3
4 65 IV II 2
5 57 III 0 2
6 61 III 0 3
7 66 IV I 2
8 61 IV I 2
9 60 III 0 3
10 74 III 0 3
Mean SD 64.8 3.9 3.5 0.7 29.4
OPCAB, Off-pump coronary artery bypass grafting; SC, stem cell; NYHA,
ventricular end-diastolic volume; SD, standard deviation.
1634 The Journal of Thoracic and Cardiovascular Surgery ● Dec6 months for the OPCAB-only group versus the OPCAB
plus stem cell therapy group: 36.4%  2.6 versus 42.1% 
3.5, 36.4%  3.0% versus 45.5%  2.2%, and 37.2% 
3.4% versus 46%  1.9%, respectively (P  .001, Figure 1).
There was one patient in the OPCAB plus stem cell therapy
group who had a hematoma at the bone marrow harvest site.
There were no other adverse events in either group (ie,
neurologic, hematologic, vascular, death, or infection
events). No patients had any postoperative arrhythmias.
Discussion
Our study is one of the first prospective randomized
approaches to cellular therapy for ischemic heart failure.
The inclusion criteria were broad to help enrollment into
the study. Exclusion criteria, however, were kept very
strict to decrease the risk to these patients with very few,
EF 1 mo
(%)
EF 3 mo
(%)
EF 6 mo
(%)
LVEDV
preoperatively
(mL)
LVEDV 6
mo (mL)
35 35 35 164 159
42 41 43 107 105
36 35 35 118 116
37 37 38 139 135
34 34 36 156 150
40 43 44 132 121
37 37 37 126 125
35 34 35 148 145
33 33 33 175 164
35 35 36 171 169
36.4 2.6 36.4  3.0 37.2 3.4 144  23 139  22
ssociation functional class; EF, ejection fraction; LVEDV, left ventricular
apy group
e EF 1 mo
(%)
EF 3 mo
(%)
EF 6 mo
(%)
LVEDV
preoperatively
(mL)
LVEDV 6
mo (mL)
39 44 44 184 152
48 50 50 111 95
43 46 47 115 97
41 45 46 168 141
43 47 46 145 136
46 47 47 133 110
39 45 45 171 133
37 43 44 176 159
39 42 45 119 98
46 46 46 109 93
42.1 3.5 45.5 2.2 46 1.9 143 29 121  26
York Heart Association functional class; EF, ejection fraction; LVEDV, leftative
)
2.5
art Ather
rativ
(%)
6
4
2
7
9
1
3
6
2
4
3.6
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disease have the potential benefit of cellular therapy from
both angiogenesis and myogenesis. Even though not all
patients had clinical myocardial infarctions, all patients
did have evidence of severely ischemic nonrevasculariz-
able regions. The 10 patients in both groups had optimal
medical therapy for their heart failure before they were
referred for the study. This information aided in the
selection process, showing which patients really have no
other treatment options.
Our results demonstrate that all the patients in the OP-
CAB plus stem cell therapy group had significantly im-
proved ejection fractions over those in the OPCAB-only
group. There was, however, also a slight improvement in the
OPCAB-only group when compared with baseline values.
This might be due to the recruiting of hibernating myocar-
dium as a result of coronary revascularization. The most
dramatic ejection fraction improvement effect was within 1
month of therapy, and this improvement was maintained
over the 6-month follow-up period. The patients improved
both on imaging studies and clinically.
A factor that might be important and might play a role in
stem cell function is the type of harvesting: direct bone
marrow aspirate or peripheral after stimulation. We evalu-
ated this concept before designing the trial. Peripheral bone
marrow harvesting requires that preoperative granulocyte
colony-stimulating factor (GCSF) be given to the patients
for 4 days before harvesting. This methodology, however,
might not be practical when planning surgical intervention
because it requires multiple procedures for the patient at
separate settings. Our rationale was based on performing a
cellular therapy where the patient would have all procedures
completed at one setting thus reducing the potential risk of
complications from the GCSF therapy, the risk of cell
contamination, the risk of multiple anesthesia, and the risk
to the quality of the cells harvested making this procedure a
safer therapy. Our volume of bone marrow harvested might
appear high at 500 to 600 mL; however, because we do not
TABLE 4. Comparison of OPCAB-only versus OPCAB plus
stem cell therapy group ejection fractions
OPCAB
OPCAB  stem cell
therapy
N 10 10
Mean EF (%)
Preoperative 30.7 2.5 29.4 3.6
1 mo 36.4 2.6 42.1 3.5*
3 mo 36.5 3.0 45.5 2.2*
6 mo 37.2 3.4 46.1 1.9*
OPCAB, Off-pump coronary artery bypass grafting; EF, ejection fraction. *P
 .001.stimulate with GCSF or culture ex vivo, this is the amount
The Journal of Thoracicwe found necessary to have adequate numbers of viable
cells. Recently, Kang and colleagues38 found that peripher-
ally harvested stem cells stimulated with GCSF increased
microinfarcts in the myocardium and did not find this to
occur with their previous work with direct bone marrow.
They believed that stimulated cells might be larger than
CD34 cells directly filtered from pure bone marrow. Until
further studies are performed to validate one technique over
the other, both will continue to be used at the preference of
the investigators.
Direct injection into the heart might have been a con-
founding factor as a result of the site of injury causing local
inflammatory angiogenesis.39 In this study 28 to 30 injec-
tions per patient were performed, and this was similar to our
pilot study. Our prior safety and efficacy study, presented at
the International Society for Heart and Lung Transplanta-
tion 2004, compared a group of 6 patients with OPCAB plus
serum injection versus OPCAB plus stem cells. The patients
with OPCAB plus stem cells had significant improvement in
their ejection fractions over a 6-month period. On the basis
of these findings, the ethics board recommended that we not
continue with serum injections in the current study. Also,
there is always the issue of stem cells with OPCAB. There
are always going to be some overlapping regions of circu-
lation. Therefore this must always be considered, but the
control group reduces some of the confounding issues.
Another factor that might contribute to stem cell function
is whether the patient was started on a cardiopulmonary
bypass machine before or during the therapy. The inflam-
matory process associated with the heart-lung machine re-
sults in the release of a number of cytokines and other
substances. This process has not been fully evaluated with
stem cells, and therefore we decided not to introduce it into
the trial. There might be no effect on stem cell function with
a cardiopulmonary bypass machine. However, that is a
question for another study.
The role of performing OPCAB might also have an
effect on stem cell function and the clinical findings. Ran-
domization was performed to decrease this confounding
variable. In our other trial, we are currently enrolling pa-
tients with nonrevascularizable CHF and performing stem
cell therapy with minimally invasive techniques to decrease
the risks of surgical intervention in these very ill patients.
The imaging techniques used in this early study, echo-
cardiography, multiplanar cardiac catheterization, and
SPECT, are simple ways that most centers could attempt to
replicate and validate our findings. In our more recent trials,
we are using gated diffusion magnetic resonance imaging.
Even though this imaging modality is very important in the
evaluation of patients with heart failure, it is limited because
it is very expensive and because of the fact that it cannot be
used in patients with implantable antiarrhythmic devices.
and Cardiovascular Surgery ● Volume 130, Number 6 1635
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for the cellular treatment of CHF demonstrates early bene-
fits. A number of questions as to the type of cells, method of
harvesting and implantation, and further mechanisms of
action will still need to be answered.40-42 None of the
previous studies have adequately addressed the differential
commitment of stem cells to either cardiomyocytes or an-
giogenesis. This might in part be dependent on the revers-
ibility of extracellular matrix changes in the myocardium
caused by CHF. Future studies will need to be performed in
which the pathology can be more closely examined. We are
planning similar studies in patients who will be unloaded by
left ventricular assist devices as a bridge to cardiac trans-
plantation. Similar work has been performed with skeletal
myoblasts by Pagani and colleagues,43 who demonstrated
viable skeletal myocytes that were injected into the scar.
However, there was no electromechanical connection, as
demonstrated by connexin 43 expression. The patient with a
ventricular assist device is a great model for future cellular
therapy trials. This will provide a unique perspective on the
specific cellular transformations that occur in ischemic car-
diomyopathy because the native heart will be excised before
transplantation. This study will help form a foundation in
surgical cellular therapy as we continue to expand our
clinical trials.37
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Discussion
Dr Robert C. Robbins (Stanford, Calif). So all the grafts were
done to the anterior wall, and the injections were done to all other
areas of the heart?
Dr Patel. Yes, sir.
Dr Robbins. And although you do mention in the article a
potential limitation that you are using this in a model of reperfu-
sion, how do you know that the improvement was not just from
coronary myocardial revascularization?
Dr Patel. That was the reason for the standard group, which
also received coronary bypass on the basis of the analysis of their
SPECT and their echocardiogram to make sure that of those 37
patients screened, the 20 who were chosen to be in the study had
very similar infarct areas. Therefore there are some confounding
variables when you revascularize, and that is why we have started
to do a minimally invasive technique in which there is no revas-
cularization for patients who have idiopathic or similar to
transmyocardial laser revascularization–type patients. Therefore
there are some confounding variables when you do this.
Dr Robbins. There are no control groups. Somebody could
stand up and argue that putting needles in the heart made them
better because you did not have a control group, but I do not buy
that.
The one thing that I will ask you to explain is that you show this
beautiful connexin 43 expression from septal biopsy specimens
that I am assuming were done from the jugular vein or an endo-
myocardial biopsy.
Dr Patel. It is from a left femoral artery retrograde.
Dr Robbins. But it is a right ventricular septal biopsy. How did
the stem cells that you are injecting not in the septum cause this
beautiful.
Dr Patel. There were injections into the septum, as I described
in the article, but these were actually left side of the heart cath-
eterizations. Therefore that is why I said the septum that is biop-
sied is from the left side of the heart, where the injections are.
Dr Robbins. So epicardially you injected cells into the septum.
How was that done?Dr Patel. With transesophageal echocardiography.
The Journal of ThoracicDr Michael Mann (San Francisco, Calif). I will try to con-
dense the question to save time. I wonder whether you could say
a few words about the preclinical animal model that you used as
the basis for these studies because I did not catch that, and this
leads into the real part of my question, which has to do with
mechanism.
Nearly every one of the dozens if not hundreds of studies that
have looked at this phenomenon have pretty much demonstrated
that there is no functional coupling of whatever cells survive this
transplantation process with the rest of the heart, and therefore I
am wondering what your hypothesized mechanism is for this
dramatic improvement on the basis of the possible survival of a
small percentage of your cells, which, granted, have not been
clearly characterized.
And also within the context of mechanism, clearly the patients
who underwent the bone marrow process were not blinded, and as
we have seen from the transmyocardial laser revascularization
studies and other studies, there is a huge placebo effect that plays
into myocardial remodeling after revascularization procedures.
How do you factor that into your analysis?
Dr Patel. To answer your last question first, in our safety and
efficacy study, which I presented this past week at the International
Society for Heart and Lung Transplantation, these patients actually
had not only the injections but also the bone marrow to serve as a
control subject for the basis of this study.
In terms of mechanism, when you look at some of these other
studies, we are not saying that these cells alone survive. There
might be a mechanism of other recruitment of not only paracrine
activity but actually a systemic response that might recruit cells,
and those are further animal studies that are ongoing. Our initial
animal model was a pig-based model that had left anterior de-
scending coronary artery ligation over time and had injection of
CD34-CD45 cells, which showed some improvement, and this led
to further analysis and then clinical trials in South America.
Our next trial, which is going to be performed here in the
United States, is actually looking at all of these theories, with a
little more in-depth analysis in patients with ventricular assist
devices so that we could harvest these hearts and get a more
specific potential mechanism and characterize the exact type of
cells that are left when these changes of just functional or clinical
improvement occur.
Dr Thoralf Sundt (Rochester, Minn). Are you saying that
these patients were blinded to their treatment group?
Dr Patel. Yes.
Dr Sundt. Therefore the patients who did not have stem cells
injected still had a bone marrow aspirate?
Dr Patel. They had an aspirate that was just frozen.
Dr Sundt. You said that these folks also had stents placed?
Dr Patel. Yes, sir.
Dr Sundt. And was it the same number of stents in everybody?
Dr Patel. It was the same number of stents before this inter-
vention.
Dr Sundt. The third thing is, this is fundamentally a regional
therapy, and yet the end point you are looking at is global, global
ejection fraction and functional class and so on. Do you have any
regional data? For example, do you have echocardiographic data
region by region that shows improvement?
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which was a little long for both this article and the article that one
of the cardiologists is going to be presenting soon. But they
actually show, region by region on the basis of what your preop-
erative dysfunction is, improvement segment by segment.
Dr Sundt. Each segment or only the segments that you in-
jected?
Dr Patel. The segments that are injected.
Dr John G. Byrne (Boston, Mass). A follow-up on Thor’s
question. In stenting, not all stenting is created equal, and therefore
obviously that is a huge confounding variable for global function.
If someone got 3 stents to the circumflex system and none to the
right, how do you control for that?
Dr Patel. These were all posterior stents, and that is why there
was almost twice the number of patients screened for this study as
opposed to actually enrolled in it. All these are confounding factors
that we tried to control, which is a little harder to do when you are
working with human subjects as opposed to a straight animal
model, but all stents were delivered to a posterior circulation. That
is why in the article you see there was one patient who received a
left anterior descending coronary artery graft and a circumflex
graft, but all posterior circulation was treated with drug-eluting
stents.
Dr Robert C. Robbins. I am going to go back to this connexin
43 stuff. I am going to give you a pass on that and say that you did
do that. Therefore are you telling us then that this increase in
connexin 43 expression was from the stem cells magically turning
into new cardiac myocytes?
Dr Patel. No, and I am glad you asked that. I was hoping you
would. In all the connexin studies that have been shown before, all
the persons who are doing myoblast therapy have failed to dem-
onstrate any connexin; even though they show global improve-
ment, there is no actual integration of these new muscles. Our
theory of mechanism is not that these cells alone become muscle,
but at the level, because these are ischemic patients, could actually
cause angiogenesis recruiting muscle that we are not currently
getting blood flow or oxygen to, along with the potential of
muscle. Therefore everyone hopes that this is just a muscle answer.
We do not believe this is a muscle-only answer. We believe this
is a combined effect, not only at a paracrine level but also there is
some systemic mechanism of recruitment, and those are the cells
and markers that we are currently looking at, at what else is going
on regionally other than these stem cells. Just to believe that these
stem cells alone turn magically into blood vessels or muscles
would not be safe or even reasonable to expect as the only answer.
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recruitment of other factors, and we are looking at cytokine levels
and other growth factors because we have shown in the animal
model that something like insulin-like growth factor or transform-
ing growth factor  have changes in the animal model in terms of
the thickness of the muscle that we are seeing in these patients at
the animal level.
Dr Carmelo A. Milano (Durham, NC). There are a number of
multicenter skeletal myoblast transplant protocols. Several of them
have required automatic implantable cardioverter defibrillators to
be present in the patients before the experiment because of the
observation of ventricular arrhythmias, and you stated that that has
not been seen. Do you have an understanding of why marrow stem
cells might not be arrhythmogenic, whereas we have these con-
cerns with skeletal myoblasts?
Dr Patel. We initially had similar concerns until we looked at
a number of different trials and our own data of more than 47
patients now. The persons who are doing the largest myoblast
studies who we have spoken to believe that it is not only the total
number of cells but also the size of cells and the injections that
are disrupting the membranes that are causing this arrhythmia
potential.
If you look at all the autologous stem cell literature, the only
trial that showed a significant amount of arrhythmia created was by
Dr Stamm in Germany, where patients were receiving both
revascularization on pump and stem cells at the same time; there
were 5 of his patients who ended up with significant arrhythmias.
We believe that being on the pump actually had some contributing
factor to this inflammatory response, not only to the disruption of
the systemic response but also actually at the cellular level, and
that was another reason why we decided not to use any perfusion
or a heart-lung machine during the stem cell implantation to cut
down the inflammatory response. To summarize, there would be
both a mechanical disruption, the number of cells, size of cells, and
the inflammatory response.
We are still very lucky and fortunate that we have not seen
these arrhythmias, but we have 5 other centers working with us
who have not seen this phenomenon either. There is no specific
answer that we could tell you yet as to why they are not having
this. But in our OPCAB data alone—forget about stem cells—our
arrhythmia rate of just postoperative atrial fibrillation is less than
5% on the basis of what the anesthesiologists give the patients of
magnesium infusions.
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OPCAB, off-pump coronary artery bypass grafting.
TABLE E1. Paired t test for NYHA functional class for OPCAB-only group
t Test: paired 2-sample test for means
Variable 1 Variable 2
Mean 3.4 2.7
Variance 0.266667 0.455556
Observations 10 10
Pearson correlation 0.382546
Hypothesized mean difference 0
df 9
t Stat 3.279649
P value (T t) 1-tailed .004767
t Critical 1-tailed 1.833113
P value (T t) 2-tailed .009535
t Critical 2-tailed 2.262157NYHA, New York Heart Association; OPCAB, off-pump coronary artery bypass grafting.
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t Test: Paired 2-sample for means
Variable 1 Variable 2
Mean 3.5 0.7
Variance 0.277778 0.677778
Observations 10 10
Pearson correlation 0.896258
Hypothesized mean difference 0
df 9
t Stat 21
P value (T t) 1-tailed 2.95E-09
t Critical 1-tailed 1.833113
P value (T t) 2-tailed 5.9E-09
t Critical 2-tailed 2.262157
NYHA, New York Heart Association; OPCAB, off-pump coronary artery bypass grafting.
TABLE E3. Paired t test for EDV for OPCAB-only group
t Test: Paired 2-sample for means
Variable 1 Variable 2
Mean 143.6 138.9
Variance 531.8222 478.1
Observations 10 10
Pearson correlation 0.988186
Hypothesized mean difference 0
df 9
t Stat 4.068624
P value (T t) 1-tailed .001403
t Critical 1-tailed 1.833114
P value (T t) 2-tailed .002805
t Critical 2-tailed 2.262159
EDV, End-diastolic volume; OPCAB, off-pump coronary artery bypass grafting.
TABLE E4. Paired t test for EDV for OPCAB plus stem cell therapy group
t Test: paired 2-sample test for means
Variable 1 Variable 2
Mean 143.1 121.4
Variance 869.2111 650.9333
Observations 10 10
Pearson correlation 0.961422
Hypothesized mean difference 0
df 9
t Stat 7.988482
P value (T t) 1-tailed 1.12E-05
t Critical 1-tailed 1.833114
P value (T t) 2-tailed 2.24E-05
t Critical 2-tailed 2.262159EDV, End-diastolic volume; OPCAB, off-pump coronary artery bypass grafting.
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